Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021
September 23, 2021 16:05 ET | Paratek Pharmaceuticals
BOSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA® (omadacycline) clinical and microbiology programs are being...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:30 ET | Paratek Pharmaceuticals
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 01, 2021 16:05 ET | Paratek Pharmaceuticals
BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria
August 18, 2021 16:12 ET | Paratek Pharmaceuticals
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021
August 09, 2021 16:05 ET | Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter -- Reported $37.9 Million in Revenue from the Delivery...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Announces NUZYRA® (omadacycline) Has Been Added to the CDC Plague Guidelines for the Treatment, Pre-Exposure and Postexposure Prophylaxis of Plague
August 04, 2021 16:30 ET | Paratek Pharmaceuticals
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021
August 03, 2021 16:30 ET | Paratek Pharmaceuticals
BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 02, 2021 16:35 ET | Paratek Pharmaceuticals
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021
August 02, 2021 16:30 ET | Paratek Pharmaceuticals
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Announces First BARDA Project BioShield Procurement of NUZYRA® (omadacycline) Valued at ~$38 Million
June 29, 2021 08:00 ET | Paratek Pharmaceuticals
BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...